Reference : Etude clinique du mois. ONTARGET: protection comparable du telmisartan et du ramipril...
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
Etude clinique du mois. ONTARGET: protection comparable du telmisartan et du ramipril et absence de benefice de la combinaison chez des patients a haut risque vasculaire.
[fr] ONTARGET: similar protection of telmisartan and ramipril and lack of benefit of combined therapy in patients at high risk for vascular events
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Krzesinski, Jean-Marie mailto [Centre Hospitalier Universitaire de Liège - CHU > > Néphrologie >]
Revue Médicale de Liège
Yes (verified by ORBi)
[en] Aged ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Benzimidazoles/therapeutic use ; Benzoates/therapeutic use ; Cardiovascular Diseases/etiology/prevention & control ; Diabetes Complications ; Drug Therapy, Combination ; Humans ; Ramipril/therapeutic use ; Risk Factors ; Treatment Outcome ; Vascular Diseases/complications
[en] ONTARGET ("ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial") compared the angiotensin converting enzyme inhibitor ramipril (10 mg/day), the angiotensin-receptor blocker telmisartan 80 mg/day, and the combination of the two drugs in 25,620 patients with vascular disease or high-risk diabetes. After a median follow up of 56 months, no significant differences were observed between the three groups neither in the primary composite outcome (death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure), nor in each of its components, total mortality and other secondary outcomes. Telmisartan was equivalent to ramipril (non inferiority criterion), but was better tolerated (less cough and angioedema). The combination of the two drugs in this population (without congestive heart failure and proteinuric nephropathy) did not bring increased benefit (no superiority), but was associated with more adverse events (hypotension, syncope and renal dysfunction). In this population, the choice of the molecule in monotherapy remains optional and the use of a dual blockade is not justified in order to have a better cardiovascular protection.
Researchers ; Professionals ; Students

File(s) associated to this reference

Fulltext file(s):

Open access
200804_10.pdfNo commentaryPublisher postprint366.45 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.